Skip to content
Screener

Integra LifeSciences IART Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Globus Medical logo
Globus MedicalGMED
$9.71M+85.9%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$868K+214%
AbbVie logo
AbbVieABBV
CONMED logo
CONMEDCNMD
Merit Medical Systems logo
Merit Medical SystemsMMSI

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.33B+33.6%
Enterprise value$3.08B+14.9%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The source filing: Integra LifeSciences’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000917520-26-000041
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Amortization of debt issuance costs and expenses associated with debt refinancing9951,385
Non-cash lease adjustment330(254)
Loss on disposal of property and equipment90495
Change in fair value of contingent consideration and others(1,293)(162)
Changes in assets and liabilities:
Accounts receivable13,64521,451
Inventories(4,329)(13,696)
Prepaid expenses and other current assets(21,877)(17,551)

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's contingent consideration fair value adjustments?
Integra LifeSciences (IART) reported contingent consideration fair value adjustments of -$1.29M in Q1 2026.
How has Integra LifeSciences's contingent consideration fair value adjustments changed year-over-year?
Integra LifeSciences's contingent consideration fair value adjustments decreased by 698.1% year-over-year, from -$162K to -$1.29M.
What is the long-term trend for Integra LifeSciences's contingent consideration fair value adjustments?
Over 4 years (2021 to 2025), Integra LifeSciences's contingent consideration fair value adjustments has grown at a 77.2% compound annual growth rate (CAGR), from -$2.16M to -$21.33M.

Ask your AI about Integra LifeSciences's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude